Erlotinib

Generic Name: Erlotinib

Brand Names: Tarceva

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃N_₃O_₄

CAS Number: 183321-74-6

Unique Ingredient Identifier: J4T82NDH7E

Background: Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

Indication: Erlotinib is indicated for:

The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.

Associated Conditions: Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer

Associated Therapies: -

Clinical Trials

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: bendamustine
Drug: erlotinib
Drug: Maintenance erlotinib

First Posted Date: 2009-02-03

Last Posted Date: 2018-04-17

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 11

Registration Number: NCT00834678

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers

Phase 2

Terminated

Conditions: Extrahepatic Bile Duct Cancer
Hepatocellular Carcinoma
Periampullary Adenocarcinoma
Gallbladder Cancer
Cholangiocellular Carcinoma
Cholangiocarcinoma of the Extrahepatic Bile Duct
Bile Duct Cancer

Interventions: Drug: Cisplatin
Drug: Erlotinib
Drug: Gemcitabine

First Posted Date: 2009-01-30

Last Posted Date: 2018-06-29

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 33

Registration Number: NCT00832637

Locations: 🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Phase 2

Terminated

Conditions: Leptomeningeal Carcinomatosis
Non-small Cell Lung Cancer

Interventions: Drug: Erlotinib

First Posted Date: 2009-01-27

Last Posted Date: 2011-07-26

Lead Sponsor: Clinical Research Center for Solid Tumor, Korea

Target Recruit Count: 20

Registration Number: NCT00830245

Locations: 🇰🇷
Dae Seog Heo, Seoul, Korea, Republic of

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer
Lung Cancer

Interventions: Drug: Dasatinib
Drug: Erlotinib

First Posted Date: 2009-01-22

Last Posted Date: 2016-06-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00826449

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Erlotinib
Drug: gemcitabine

First Posted Date: 2008-12-18

Last Posted Date: 2018-01-10

Lead Sponsor: University of California, Davis

Target Recruit Count: 30

Registration Number: NCT00810719

Locations: 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma

Phase 1

Terminated

Conditions: Liver Carcinoma

Interventions: Drug: AVE1642
Drug: sorafenib
Drug: erlotinib

First Posted Date: 2008-11-14

Last Posted Date: 2010-08-04

Lead Sponsor: Sanofi

Target Recruit Count: 13

Registration Number: NCT00791544

Locations: 🇫🇷
Sanofi-Aventis Administrative Office, Paris, France

Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib

Phase 2

Conditions: Metastatic Colorectal Cancer

First Posted Date: 2008-11-04

Last Posted Date: 2010-11-30

Lead Sponsor: Austin Health

Target Recruit Count: 50

Registration Number: NCT00784667

Locations: 🇦🇺
Royal North Shore Hospital, Sydney, New South Wales, Australia
🇦🇺
Ballarat Base Hospital, Ballarat, Victoria, Australia
🇦🇺
Austin Health, Melbourne, Victoria, Australia

and more 1 locations